Phio Pharmaceuticals Corp. (PHIOW) Stock Analysis
DELISTED 2022
What happened to Phio Pharmaceuticals Corp. (PHIOW) stock?
Phio Pharmaceuticals Corp. (PHIOW) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Phio Pharmaceuticals Corp. (PHIOW) trades at $0.0232. Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics using its INTASYL platform to silence tumor-induced suppression of the immune system. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for PHIOW: PHIOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PHIOW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
PHIOW: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Phio Pharmaceuticals Corp. (PHIOW) Healthcare & Pipeline Overview
Phio Pharmaceuticals Corp. is a biotechnology firm specializing in immuno-oncology therapeutics, utilizing its INTASYL platform to develop treatments that enhance the immune system's ability to fight cancer by silencing tumor-induced suppression, positioning them in the competitive and rapidly evolving biotechnology landscape.
What Is the Investment Thesis for PHIOW?
Phio Pharmaceuticals Corp. presents a high-risk, high-reward investment opportunity within the immuno-oncology sector. The company's INTASYL platform offers a novel approach to cancer treatment by silencing tumor-induced immune suppression. Key value drivers include the successful preclinical and clinical development of PH-762, PH-804, and PH-790. Upcoming data readouts from ongoing studies and potential partnerships with larger pharmaceutical companies could serve as catalysts. However, the company's limited market capitalization of $0.00B and negative P/E ratio of -1.70, coupled with the inherent risks of drug development, including regulatory hurdles and clinical trial failures, pose significant challenges. The company's success hinges on demonstrating the efficacy and safety of its drug candidates in human trials.
Based on FMP financials and quantitative analysis
PHIOW Key Highlights
Phio Pharmaceuticals focuses on Immuno-oncology therapeutics through its INTASYL platform.
- The company's pipeline includes PH-762, PH-804, and PH-790, targeting PD-1, TIGIT, and PD-L1, respectively.
- Phio collaborates with Gustave Roussy, Medigene AG, Helmholtz Zentrum München, and AgonOx Inc.
- The company has a market capitalization of $0.00B.
- Phio Pharmaceuticals has a P/E ratio of -1.70, indicating it is not currently profitable.
Who Are PHIOW's Competitors?
PHIOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| LSB LakeShore Biopharma Co., Ltd | $0.63 | +0.00% | $25.8M | 46 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PHIOW's Key Strengths?
Proprietary INTASYL platform.
- Pipeline of immuno-oncology therapeutics.
- Strategic collaborations.
- Experienced management team.
What Are PHIOW's Weaknesses?
Limited financial resources.
- Early-stage development pipeline.
- Dependence on collaborations.
- Small number of employees.
What Could Drive PHIOW Stock Higher?
Data readouts from ongoing clinical trials of PH-762, PH-804, and PH-790.
- Potential for new strategic collaborations with pharmaceutical companies.
- Advancement of the INTASYL platform into new therapeutic areas.
What Are the Key Risks for PHIOW?
Financial-distress signal — its Altman Z-Score of -15.22 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies with greater resources.
- Dependence on collaborations for funding and expertise.
- Patent expirations and loss of intellectual property protection.
What Are the Growth Opportunities for PHIOW?
- Development of PH-762 for Adoptive Cell Transfer: Phio's lead candidate, PH-762, targets the PD-1 checkpoint protein and is designed to enhance the efficacy of adoptive cell transfer (ACT) therapies. The market for ACT therapies is growing, with projections estimating a multi-billion dollar market size by 2030. Successful clinical trials and subsequent regulatory approval could position PH-762 as a valuable component of ACT regimens, offering a significant growth opportunity for Phio.
- Advancement of PH-804 Targeting TIGIT: PH-804, which targets the TIGIT immune receptor, represents another promising growth avenue. TIGIT is a checkpoint protein present on T cells and natural killer cells, and blocking it can enhance immune responses against tumors. The market for TIGIT-targeting therapies is still emerging, but early clinical data suggest significant potential. Phio's development of PH-804 could position it as a leader in this space, with potential for substantial revenue generation.
- Expansion of INTASYL Platform Applications: The INTASYL platform, which silences tumor-induced suppression of the immune system, has the potential to be applied to a wide range of cancer types and therapeutic modalities. Expanding the applications of the INTASYL platform beyond the current pipeline could unlock new growth opportunities for Phio. This could involve developing new drug candidates or partnering with other companies to incorporate INTASYL into their therapies.
- Strategic Collaborations and Partnerships: Phio's existing collaborations with institutions like Gustave Roussy and companies like Medigene AG and AgonOx Inc. demonstrate its ability to form strategic partnerships. Pursuing additional collaborations with larger pharmaceutical companies or research institutions could provide access to funding, expertise, and resources needed to accelerate the development and commercialization of its therapies. These partnerships could also validate the value of Phio's technology and increase its visibility within the industry.
- Addressing Unmet Needs in Cancer Immunotherapy: Despite the advances in cancer immunotherapy, many patients do not respond to existing treatments. Phio's approach of silencing tumor-induced immune suppression offers a potential solution to this problem. By addressing this unmet need, Phio could capture a significant share of the cancer immunotherapy market. This requires demonstrating the superiority of its therapies in clinical trials and effectively communicating the value proposition to healthcare providers and patients.
What Are PHIOW's Competitive Advantages?
- Proprietary INTASYL therapeutic platform for silencing tumor-induced immune suppression.
- Pipeline of novel drug candidates targeting key immune checkpoints.
- Strategic collaborations with leading research institutions and pharmaceutical companies.
- Strong intellectual property protection for its technologies and drug candidates.
What Does PHIOW Do?
Phio Pharmaceuticals Corp., established in 2011 and headquartered in Marlborough, Massachusetts, is a biotechnology company dedicated to developing innovative immuno-oncology therapeutics. The company's core technology is the INTASYL therapeutic platform, which focuses on silencing genes that contribute to the suppression of the immune system by tumors. This approach aims to enhance the body's natural ability to fight cancer. Phio's pipeline includes several drug candidates designed for adoptive cell transfer (ACT). These include PH-762, which targets the checkpoint protein PD-1 on immune cells; PH-804, which targets the suppressive immune receptor TIGIT present on T cells and natural killer cells; and PH-790, which targets the PD-L1 protein that prevents immune cells from attacking nonharmful cells. These candidates are designed to improve the efficacy of ACT therapies by overcoming the immunosuppressive environment created by tumors. Phio Pharmaceuticals collaborates with several institutions and companies, including Gustave Roussy, Medigene AG, Helmholtz Zentrum München, and AgonOx Inc., to advance the clinical development of its novel T cell-based cancer immunotherapies. Formerly known as RXi Pharmaceuticals Corporation, the company changed its name to Phio Pharmaceuticals Corp. in November 2018, reflecting its strategic focus on immuno-oncology.
What Products and Services Does PHIOW Offer?
- Develop immuno-oncology therapeutics.
- Utilize the INTASYL therapeutic platform to silence tumor-induced suppression of the immune system.
- Develop PH-762, a drug candidate targeting the checkpoint protein PD-1.
- Develop PH-804, a drug candidate targeting the suppressive immune receptor TIGIT.
- Develop PH-790, a drug candidate targeting the PD-L1 protein.
- Collaborate with research institutions and other companies to advance clinical development.
How Does PHIOW Make Money?
- Develop and patent novel immuno-oncology therapeutics.
- Out-license or partner with larger pharmaceutical companies for clinical development and commercialization.
- Generate revenue through milestone payments and royalties on sales of approved products.
What Industry Does PHIOW Operate In?
Phio Pharmaceuticals operates in the competitive biotechnology industry, specifically within the immuno-oncology segment. This segment is characterized by rapid innovation and significant investment, driven by the increasing prevalence of cancer and the demand for more effective treatments. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share with innovative approaches to cancer treatment.
Who Are PHIOW's Key Customers?
- Pharmaceutical companies seeking novel immuno-oncology therapeutics.
- Research institutions interested in collaborating on drug development.
- Patients with cancer who may benefit from Phio's therapies.
Company Profile
Phio Pharmaceuticals Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Marlborough, US. The company is led by CEO Gerrit Dispersyn Med. Sc. PHIOW has traded publicly since 2012.
Financial Health
Phio Pharmaceuticals Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.22 places it in the distress zone, a signal of elevated financial risk.
PHIOW Financials
Bull Case vs Bear Case
Bull Case
- Phio's recent insider buying suggests those in the know see long-term potential, signaling confidence.
- The community buzz seems optimistic about Phio's RNAi-based therapies, especially their potential in immuno-oncology.
- Market perception is shifting towards personalized medicine, potentially benefiting companies like Phio focused on targeted therapies.
- Positive developments in RNAi tech, similar to the early days of gene editing, create a favorable environment for Phio.
Bear Case
- Recent market volatility could disproportionately affect smaller biotech firms like Phio, reminiscent of the dot-com bust's impact on emerging tech.
- Community sentiment, while generally positive, shows concerns about Phio's cash burn rate and need for future funding.
- The long timelines and high failure rates associated with drug development, mirroring past biotech struggles, remain a significant risk.
- Competition in the RNAi therapeutics space is intensifying, potentially limiting Phio's market share, much like the crowded electric vehicle market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PHIOW Latest News
No recent news available for PHIOW.
Leadership: Gerrit Dispersyn Med. Sc
Chief Executive Officer
Gerrit Dispersyn brings extensive experience in the biotechnology and pharmaceutical industries to his role as CEO of Phio Pharmaceuticals. His background includes leadership positions in various companies focused on drug development and commercialization. He has a strong track record in strategic planning, business development, and clinical operations. His Med. Sc. degree provides a deep understanding of the scientific and medical aspects of the company's work.
Track Record: Since joining Phio Pharmaceuticals, Gerrit Dispersyn has focused on advancing the company's immuno-oncology pipeline and securing strategic collaborations. Key achievements include progressing PH-762, PH-804, and PH-790 through preclinical development and initiating clinical trials. He has also been instrumental in forging partnerships with research institutions and pharmaceutical companies to support the company's growth.
What Investors Ask About Phio Pharmaceuticals Corp. (PHIOW) — Healthcare
What happened to Phio Pharmaceuticals Corp. (PHIOW) stock?
Phio Pharmaceuticals Corp. (PHIOW) no longer trades on public markets. It was delisted in December 2022. The figures below are historical and are not a current quote.
Can I still buy PHIOW shares?
No. PHIOW stopped trading on public markets in December 2022, so the shares are not available through a broker. Anything you see quoted for PHIOW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PHIOW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Phio Pharmaceuticals Corp.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Phio Pharmaceuticals Corp. do?
Phio Pharmaceuticals Corp. is a biotechnology company focused on developing immuno-oncology therapeutics. The company's core technology is the INTASYL therapeutic platform, which silences genes that contribute to the suppression of the immune system by tumors. This approach aims to enhance the body's natural ability to fight cancer. Phio is developing drug candidates targeting key immune checkpoints, such as PD-1, TIGIT, and PD-L1, to improve the efficacy of cancer immunotherapies.
What are the main risks for PHIOW?
Phio Pharmaceuticals faces several key risks inherent to the biotechnology industry. These include the risk of clinical trial failures, which could halt the development of its drug candidates. Regulatory hurdles and delays in drug approval also pose a significant risk. Competition from larger pharmaceutical companies with greater resources is another challenge.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- AI analysis is pending and may provide additional insights.